Details

Autor(en) / Beteiligte

• Giuliano, Anna R
• Palefsky, Joel M
• Goldstone, Stephen
• Moreira, Edson D
• Penny, Mary E
• Aranda, Carlos
• Vardas, Eftyhia
• Moi, Harald
• Jessen, Heiko
• Hillman, Richard
• Chang, Yen-Hwa
• Ferris, Daron
• Rouleau, Danielle
• Bryan, Janine
• Marshall, J. Brooke
• Vuocolo, Scott
• Barr, Eliav
• Radley, David
• Haupt, Richard M
• Guris, Dalya

Titel

Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males

Ist Teil von

• The New England journal of medicine, 2011-02, Vol.364 (5), p.401-411

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2011

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Limited data on the efficacy of the quadrivalent HPV vaccine are available for males. In this trial involving 4065 healthy boys and young men 16 to 26 years of age, the quadrivalent vaccine against HPV reduced the occurrence of external genital lesions by 60%. Human papillomavirus (hpv) infects the squamous epithelium in both sexes, leading to anogenital condylomata acuminata and, in males, to cancers of the penis, anus, and oropharynx. 1 The rate of genital HPV infection among males is similar to that in females. In any 12-month period, the probability that a sexually active male will acquire a new genital HPV infection is 0.29 to 0.39, 2 – 4 which is similar to estimates for females. However, there are differences between the sexes in the immune response to HPV. A larger proportion of females are HPV-seropositive (17.9%, vs. 7.9% of males), and females . . .